Licensing & Partnering

Splendris Pharmaceuticals GmbH is  interested in license-in the following medicinal products for human health.

Our partnership model is highly flexible. We are interested in products, marketing authorisations, dossiers, and the technology of formulation and/or APIs.

  • Cefuroxime Axetil Tablets (124 mg, 250 mg)
  • Clopidogrel/Acetylsalicylic Acid Entero Tablets (75 mg/75 mg, 75 mg/100 mg)
  • Dapoxetine Tablets (30 mg, 60 mg)
  • Erlotinib Tablets (100 mg, 150 mg)
  • Ezetimible Tablets (10 mg)
  • Ezetimibe/Simvastatin Tablets (10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, 10 mg/80 mg)
  • Fluvastatin Extended Release Tablets (80 mg)
  • Imatinib Tablets (100 mg, 400 mg)
  • Ivabradine Tablets (5 mg, 7.5 mg)
  • Levetiracetam Injection (500 mg/5 ml)
  • Levetiracetam Oral Solution (100 mg/ml)
  • Lercanidipine Tablets (10 mg)
  • Moxifloxacin Tablets (400 mg)
  • Pitavastatin Tablets (1 mg, 2 mg)
  • Olmesartan Tablets (20 mg)
  • Rosuvastatin Tablets (5 mg, 10 mg, 20 mg, 40 mg)
  • Valsartan Tablets (40 mg, 80 mg, 160 mg, 320 mg)

Contact us now online: contact form.